Stock RAIN RAIN ONCOLOGY INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Rain Oncology Inc.

Equities

RAIN

US75082Q1058

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rain Oncology Acquisition by Pathos AI Completed
MT
Pathos AI Completes Acquisition of Rain Oncology
BU
Rain Oncology Inc.(NasdaqGS:RAIN) dropped from NASDAQ Composite Index
CI
Rain Oncology Inc.(NasdaqGS:RAIN) dropped from S&P TMI Index
CI
Pathos AI, Inc. completed the acquisition of Rain Oncology Inc. on January 26, 2024.
CI
RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN
BU
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICVX, DSKE, RAIN, CNSL
PR
RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN
BU
Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos
PR
Rain Oncology Agrees to be Acquired by Pathos AI
MT
RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders
BU
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
AQ
Rain Oncology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
AQ
Rain Oncology Insider Bought Shares Worth $279,030, According to a Recent SEC Filing
MT
Concentra Biosciences, LLC submits a non-binding proposal to acquire Rain Oncology Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others for $45.5 million.
CI
Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating
MT
The Gross Law Firm Notifies Shareholders of Rain Oncology Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 12, 2023 - (NASDAQ: RAIN)
PR
ROSEN, A TOP RANKED LAW FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action - RAIN
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RAIN Stock
  4. News Rain Oncology Inc.